Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, Elena Startseva, Anna Unseld, Anita M. Hennige
Topics & Concepts
MedicinePlaceboAgonistGlucagon-like peptide 1 receptorLiraglutideGlucagon-like peptide-1Double blindInternal medicineDiabetes mellitusPharmacologyEndocrinologyType 2 diabetesReceptorAlternative medicinePathologyDiabetes Treatment and ManagementBariatric Surgery and OutcomesPharmacology and Obesity Treatment